QR Code
Salas-Silva, Soraya; Simoni-Nieves, Arturo; Valeria Razori, Maria; Lopez-Ramirez, Jocelyn; Barrera-Chimal, Jonatan; Lazzarini, Roberto; Bello, Oscar; Souza, Veronica; Miranda-Labra, Roxana U; Concepcion Gutierrez-Ruiz, Maria; Enrique Gomez-Quiroz, Luis; Roma, Marcelo G; Bucio-Ortiz, Leticia (2020)


Biochem. Pharmacol. 174():
full text

Cholestasis is a clinical syndrome common to a large number of hepatopathies, in which either bile production or its transit through the biliary tract is impaired due to functional or obstructive causes; the consequent intracellular retention of toxic biliary constituents generates parenchyma damage, largely via oxidative stress-mediated mechanisms. Hepatocyte growth factor (HGF) and its receptor c-Met represent one of the main systems for liver repair damage and defense against hepatotoxic factors, leading to an antioxidant and repair response. In this study, we evaluated the capability of HGF to counteract the damage caused by the model cholestatic agent, α-naphthyl isothiocyanate (ANIT). HGF had clear anti-cholestatic effects, as apparent from the improvement in both bile flow and liver function test. Histology examination revealed a significant reduction of injured areas. HGF also preserved the tight-junctional structure. These anticholestatic effects were associated with the induction of basolateral efflux ABC transporters, which facilitates extrusion of toxic biliary compounds and its further alternative depuration via urine. The biliary epithelium seems to have been also preserved, as suggested by normalization in serum GGT levels, CFTR expression and cholangyocyte primary cilium structure our results clearly show for the first time that HGF protects the liver from a cholestatic injury.